LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

Search

Arcutis Biotherapeutics Inc

Aperta

SettoreSettore sanitario

15.21 -1.93

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

15.11

Massimo

15.69

Metriche Chiave

By Trading Economics

Entrata

9.2M

-16M

Vendite

16M

82M

Margine di Profitto

-19.491

Dipendenti

342

EBITDA

6.7M

-12M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+38.27% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

186M

1.9B

Apertura precedente

17.14

Chiusura precedente

15.21

Notizie sul Sentiment di mercato

By Acuity

50%

50%

172 / 372 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 ago 2025, 22:51 UTC

Utili

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H Rev $4.01B

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H Adj EPS $1.84

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H EPS $1.82

27 ago 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 ago 2025, 23:39 UTC

Utili

Correction to Nvidia Earnings Article -- WSJ

27 ago 2025, 22:59 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 ago 2025, 22:59 UTC

Discorsi di Mercato

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 ago 2025, 22:58 UTC

Utili

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 ago 2025, 22:57 UTC

Utili

South32 FY Free Cash Flow $192 Million

27 ago 2025, 22:56 UTC

Utili

South32 FY Total Capital Expenditure $1.35 Billion

27 ago 2025, 22:56 UTC

Utili

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 ago 2025, 22:55 UTC

Utili

South32 Net Cash $123 Million at June 30

27 ago 2025, 22:54 UTC

Utili

South32: Focused on Maintaining Strong Operating Momentum

27 ago 2025, 22:53 UTC

Utili

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 ago 2025, 22:53 UTC

Utili

South32 Extends Capital Management Program for 12 Months

27 ago 2025, 22:52 UTC

Utili

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 ago 2025, 22:51 UTC

Utili

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 ago 2025, 22:51 UTC

Utili

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 ago 2025, 22:50 UTC

Utili

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 ago 2025, 22:50 UTC

Utili

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 ago 2025, 22:45 UTC

Utili

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 ago 2025, 22:44 UTC

Utili

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 ago 2025, 22:44 UTC

Utili

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 ago 2025, 22:43 UTC

Utili

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 ago 2025, 22:43 UTC

Utili

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 ago 2025, 22:42 UTC

Utili

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 ago 2025, 22:42 UTC

Utili

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 ago 2025, 22:40 UTC

Utili

Sandfire Resources Net Debt $123 Million at June 30

27 ago 2025, 22:40 UTC

Utili

Sandfire Resources FY Underlying Ebitda $527.7 Million

Confronto tra pari

Modifica del prezzo

Arcutis Biotherapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

38.27% in crescita

Previsioni per 12 mesi

Media 21.64 USD  38.27%

Alto 29 USD

Basso 14.29 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

7

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

12.42 / 14.93Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

172 / 372 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.